Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment

Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment

US Patent 11235037 · Granted Feb 1, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Surgical stapling device with powered handle assembly2025
Human pluripotent stem cell-based screening for smooth muscle cell differentiati2025
Protein conjugates2025
Protein conjugates2025
Protein conjugates2025
Reprogramming somatic cells into pluripotent cells using a vector encoding Oct4 2024
Generating arterial endothelial cell populations2023
Expansion and maintenance of adult primary human hepatocytes in culture2023
Generating arterial endothelial cell-seeded vascular grafts2022
Human pluripotent stem cell-based system for generating endothelial cells2022
Derivation of human microglia from pluripotent stem cells2021
Generation of uniform hepatocytes from human embryonic stem cells by inhibiting 2021